What is Zacks Research’s Forecast for Omnicell Q1 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Analysts at Zacks Research boosted their Q1 2025 earnings per share estimates for Omnicell in a research note issued to investors on Thursday, November 14th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $0.15 for the quarter, up from their prior estimate of $0.14. The consensus estimate for Omnicell’s current full-year earnings is $0.74 per share. Zacks Research also issued estimates for Omnicell’s Q2 2025 earnings at $0.18 EPS.

A number of other research firms have also recently commented on OMCL. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research report on Friday. Barclays boosted their price objective on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. Bank of America reaffirmed a “neutral” rating and issued a $57.00 price target (up previously from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. JPMorgan Chase & Co. boosted their price objective on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 23rd. Finally, Benchmark reiterated a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a report on Wednesday, October 9th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $50.83.

Omnicell Trading Down 2.0 %

Shares of OMCL stock opened at $45.67 on Monday. The stock has a 50 day moving average of $44.20 and a 200 day moving average of $36.89. The stock has a market cap of $2.12 billion, a P/E ratio of -117.10, a P/E/G ratio of 43.97 and a beta of 0.81. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.74.

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently bought and sold shares of OMCL. Vanguard Group Inc. increased its position in Omnicell by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock worth $165,200,000 after buying an additional 80,312 shares in the last quarter. Pacer Advisors Inc. boosted its holdings in Omnicell by 32.6% in the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after acquiring an additional 508,789 shares during the last quarter. Champlain Investment Partners LLC lifted its stake in shares of Omnicell by 16.0% during the first quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after purchasing an additional 241,235 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Omnicell by 0.3% during the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after purchasing an additional 3,570 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of Omnicell by 11,982.3% during the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after purchasing an additional 1,138,921 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.